Changing the research criteria for the diagnosis of Parkinson's disease: Obstacles and opportunities

Daniela Berg; Anthony E. Lang; Ronald B. Postuma; Walter Maetzler; Guenther Deuschl; Thomas Gasser; Andrew Siderowf; Anthony H. Schapira; Wolfgang Oertel; José A. Obeso; C. Warren Olanow; Werner Poewe; Matthew Stern

doi:10.1016/S1474-4422(13)70047-4

Changing the research criteria for the diagnosis of Parkinson's disease: Obstacles and opportunities

Daniela Berg
, Anthony E. Lang
, Ronald B. Postuma
, Walter Maetzler
, Guenther Deuschl
, Thomas Gasser
, Andrew Siderowf
, Anthony H. Schapira
, Wolfgang Oertel
, José A. Obeso
, C. Warren Olanow
, Werner Poewe
, Matthew Stern

Research output: Contribution to journal › Comment/debate

138 Scopus citations

Original language	English
Pages (from-to)	514-524
Number of pages	11
Journal	The Lancet Neurology
Volume	12
Issue number	5
DOIs	https://doi.org/10.1016/S1474-4422(13)70047-4
State	Published - May 2013

Access to Document

10.1016/S1474-4422(13)70047-4

Cite this

@article{2e429863fc7143d7ae9b33dd46f8ef28,

title = "Changing the research criteria for the diagnosis of Parkinson's disease: Obstacles and opportunities",

author = "Daniela Berg and Lang, \{Anthony E.\} and Postuma, \{Ronald B.\} and Walter Maetzler and Guenther Deuschl and Thomas Gasser and Andrew Siderowf and Schapira, \{Anthony H.\} and Wolfgang Oertel and Obeso, \{Jos{\'e} A.\} and Olanow, \{C. Warren\} and Werner Poewe and Matthew Stern",

note = "Funding Information: DB has served on advisory boards for Novartis and UCB Pharma; has received honoraria from UCB Pharma, GlaxoSmithKline, TEVA, and Lundbeck; and has received grants from the Michael J Fox Foundation, Bundesministerium f{\"u}r Bildung und Forschung (BmBF), dPV (German Parkinson's disease association), Abbott, Center of Integrative Neurosciences, Internationale Parkinson Fonds, Janssen, TEVA, and UCB Pharma. AEL has served as an advisor for Abbott, Allon Therapeutics, AstraZeneca, Avanir Pharmaceuticals, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Ceregene, Eisai, GlaxoSmithKline, Lundbeck, Medtronic, Merck Serono, MSD, Novartis, Santhera, Solvay, and TEVA; has received grants from The Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J Fox Foundation, National Parkinson Foundation, Parkinson Society of Canada, and Ontario Problem Gambling Research Center; has received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and has served as an expert witness in cases related to the welding industry. RP has received travel expenses and speaker fees from Novartis and TEVA, and is funded by grants from the Fonds de la Recherche en Sant{\'e} du Quebec, the Parkinson Society of Canada, the Webster Foundation, and the Canadian Institutes of Health Research. WM has received research support from the Robert Bosch Foundation and speaker honoraria from GlaxoSmithKline. WM receives research support from the EU and the University of T{\"u}bingen. GD has received lecture fees from Orion, Lundbeck, TEVA, and Pfizer, and has served as a consultant for TEVA. GD receives royalties from Thieme publishers. GD's institution receives funding from the German Ministry of Education and Health and Medtronic. TG has received consultation fees from Cefalon Pharma and Merck-Serono, and lecture fees from Boehringer Ingelheim, Merck-Serono, Valeant Pharma, and UCB Pharma. TG holds a patent concerning the LRRK2 gene and use for detection and treatment of neurodegenerative disorders. TG receives funding from Novartis, the Federal Ministry of Education and Research, the Helmholtz Association, and the European Community. AS is an employee of Avid Radiopharmaceuticals. AHS has received honoraria or undertaken consultancy work for Boehringer Ingelheim, GlaxoSmithKline, TEVA-Lundbeck, Orion-Novartis, and MSD-Serono. WO holds stock in Roche 100; has served as a consultant for Desitin, Novartis, Orion Pharma, Phytopharm, Synosia, Bayer-Schering, Boehringer Ingelheim, Medtronic, MSD, Schwarz Pharma, Neuroscience/UCB, and TEVA; has received honoraria from GlaxoSmithKline, Novartis, and Orion Pharma; and has received grants from the German Ministry of Education and Research, Michael J Fox Foundation, and Internationale Parkinson Fonds. JAO has served on an advisory board for GlaxoSmithKline, has received honoraria for lecturing at meetings organised by GlaxoSmithKline, Lundbeck-TEVA, and UCB, and has received grants or research funding from the Spanish Science and Education Ministry and European Union (REPLACES). CWO is on the executive committee of the Michael J Fox Foundation, serves on the board of directors of the National Space Board Research Institute, and has served as an expert witness in the manganese defence litigation. WP has received consultancy and lecture fees from Abbott, AstraZeneca, TEVA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma, Merck Serono, and Merz Pharmaceuticals. MS has served as a consultant for TEVA, Adarnas, Cevitas, Merz, and Medtronic.",

year = "2013",

month = may,

doi = "10.1016/S1474-4422(13)70047-4",

language = "English",

volume = "12",

pages = "514--524",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "Elsevier Ltd.",

number = "5",

}

TY - JOUR

T1 - Changing the research criteria for the diagnosis of Parkinson's disease

T2 - Obstacles and opportunities

AU - Berg, Daniela

AU - Lang, Anthony E.

AU - Postuma, Ronald B.

AU - Maetzler, Walter

AU - Deuschl, Guenther

AU - Gasser, Thomas

AU - Siderowf, Andrew

AU - Schapira, Anthony H.

AU - Oertel, Wolfgang

AU - Obeso, José A.

AU - Olanow, C. Warren

AU - Poewe, Werner

AU - Stern, Matthew

N1 - Funding Information: DB has served on advisory boards for Novartis and UCB Pharma; has received honoraria from UCB Pharma, GlaxoSmithKline, TEVA, and Lundbeck; and has received grants from the Michael J Fox Foundation, Bundesministerium für Bildung und Forschung (BmBF), dPV (German Parkinson's disease association), Abbott, Center of Integrative Neurosciences, Internationale Parkinson Fonds, Janssen, TEVA, and UCB Pharma. AEL has served as an advisor for Abbott, Allon Therapeutics, AstraZeneca, Avanir Pharmaceuticals, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Ceregene, Eisai, GlaxoSmithKline, Lundbeck, Medtronic, Merck Serono, MSD, Novartis, Santhera, Solvay, and TEVA; has received grants from The Canadian Institutes of Health Research, Dystonia Medical Research Foundation, Michael J Fox Foundation, National Parkinson Foundation, Parkinson Society of Canada, and Ontario Problem Gambling Research Center; has received publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press, and Cambridge University Press; and has served as an expert witness in cases related to the welding industry. RP has received travel expenses and speaker fees from Novartis and TEVA, and is funded by grants from the Fonds de la Recherche en Santé du Quebec, the Parkinson Society of Canada, the Webster Foundation, and the Canadian Institutes of Health Research. WM has received research support from the Robert Bosch Foundation and speaker honoraria from GlaxoSmithKline. WM receives research support from the EU and the University of Tübingen. GD has received lecture fees from Orion, Lundbeck, TEVA, and Pfizer, and has served as a consultant for TEVA. GD receives royalties from Thieme publishers. GD's institution receives funding from the German Ministry of Education and Health and Medtronic. TG has received consultation fees from Cefalon Pharma and Merck-Serono, and lecture fees from Boehringer Ingelheim, Merck-Serono, Valeant Pharma, and UCB Pharma. TG holds a patent concerning the LRRK2 gene and use for detection and treatment of neurodegenerative disorders. TG receives funding from Novartis, the Federal Ministry of Education and Research, the Helmholtz Association, and the European Community. AS is an employee of Avid Radiopharmaceuticals. AHS has received honoraria or undertaken consultancy work for Boehringer Ingelheim, GlaxoSmithKline, TEVA-Lundbeck, Orion-Novartis, and MSD-Serono. WO holds stock in Roche 100; has served as a consultant for Desitin, Novartis, Orion Pharma, Phytopharm, Synosia, Bayer-Schering, Boehringer Ingelheim, Medtronic, MSD, Schwarz Pharma, Neuroscience/UCB, and TEVA; has received honoraria from GlaxoSmithKline, Novartis, and Orion Pharma; and has received grants from the German Ministry of Education and Research, Michael J Fox Foundation, and Internationale Parkinson Fonds. JAO has served on an advisory board for GlaxoSmithKline, has received honoraria for lecturing at meetings organised by GlaxoSmithKline, Lundbeck-TEVA, and UCB, and has received grants or research funding from the Spanish Science and Education Ministry and European Union (REPLACES). CWO is on the executive committee of the Michael J Fox Foundation, serves on the board of directors of the National Space Board Research Institute, and has served as an expert witness in the manganese defence litigation. WP has received consultancy and lecture fees from Abbott, AstraZeneca, TEVA, Novartis, GlaxoSmithKline, Boehringer Ingelheim, UCB, Orion Pharma, Merck Serono, and Merz Pharmaceuticals. MS has served as a consultant for TEVA, Adarnas, Cevitas, Merz, and Medtronic.

PY - 2013/5

Y1 - 2013/5

UR - https://www.scopus.com/pages/publications/84876464458

U2 - 10.1016/S1474-4422(13)70047-4

DO - 10.1016/S1474-4422(13)70047-4

M3 - Comment/debate

C2 - 23582175

AN - SCOPUS:84876464458

SN - 1474-4422

VL - 12

SP - 514

EP - 524

JO - The Lancet Neurology

JF - The Lancet Neurology

IS - 5

ER -